Log in

NASDAQ:OPK - Opko Health Stock Price, Forecast & News

$1.36
-0.04 (-2.86 %)
(As of 03/31/2020 09:19 AM ET)
Today's Range
$1.32
Now: $1.36
$1.39
50-Day Range
$1.36
MA: $1.62
$2.32
52-Week Range
$1.32
Now: $1.36
$2.91
Volume11.50 million shs
Average Volume31.50 million shs
Market Capitalization$910.97 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
Read More
Opko Health logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:OPK
CUSIP68375N10
Phone305-575-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$901.90 million
Book Value$2.43 per share

Profitability

Net Income$-314,920,000.00

Miscellaneous

Employees6,096
Market Cap$910.97 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive OPK News and Ratings via Email

Sign-up to receive the latest news and ratings for OPK and its competitors with MarketBeat's FREE daily newsletter.


Opko Health (NASDAQ:OPK) Frequently Asked Questions

How has Opko Health's stock been impacted by COVID-19 (Coronavirus)?

Opko Health's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, OPK stock has decreased by 19.5% and is now trading at $1.36. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Opko Health?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opko Health in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opko Health.

When is Opko Health's next earnings date?

Opko Health is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Opko Health.

How were Opko Health's earnings last quarter?

Opko Health Inc. (NASDAQ:OPK) issued its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.02. The biotechnology company earned $228.80 million during the quarter, compared to analysts' expectations of $225.40 million. Opko Health had a negative net margin of 34.92% and a negative return on equity of 14.41%. The business's quarterly revenue was down 8.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) earnings per share. View Opko Health's earnings history.

What price target have analysts set for OPK?

3 equities research analysts have issued twelve-month price objectives for Opko Health's shares. Their forecasts range from $2.50 to $4.00. On average, they anticipate Opko Health's share price to reach $3.17 in the next twelve months. This suggests a possible upside of 132.8% from the stock's current price. View analysts' price targets for Opko Health.

What are Wall Street analysts saying about Opko Health stock?

Here are some recent quotes from research analysts about Opko Health stock:
  • 1. According to Zacks Investment Research, "OPKO Health has gained significantly from RAYALDEE contribution in recent times. Further, OPKO Health’s utilization of the 4Kscore remains strong, with nearly 18,800 tests registered in the second quarter. These apart, the company’s clinical development programs look promising with a robust pipeline of candidates. Several metabolic and endocrinology programs that are underway should provide OPKO Health a competitive advantage. However, the company’s gross margin is under pressure at the moment. Moreover, the company faces cutthroat competition in the MedTech space. Sluggishness in the Services revenue segment remains a concern. OPKO Health underperformed its industry in a year’s time." (10/18/2019)
  • 2. Barrington Research analysts commented, "We continue to rate OPK shares an OUTPERFORM and our price target remains $4. That said, if the company were to receive a strong data readout from its Phase III trial for hGH‐CTP within the next few months, we suspect that shares would rally meaningfully from current levels and that investor sentiment could swing positive for the first time in over four years. We arrive at our price target via a DCF methodology. It is important to note that the company still has many “shots on goal” within its current commercial portfolio and product development pipeline." (9/12/2019)

Has Opko Health been receiving favorable news coverage?

Media stories about OPK stock have been trending neutral this week, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Opko Health earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutOpko Health.

Are investors shorting Opko Health?

Opko Health saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 95,302,400 shares, an increase of 13.4% from the February 27th total of 84,040,000 shares. Based on an average daily trading volume, of 31,108,300 shares, the days-to-cover ratio is currently 3.1 days. Currently, 23.8% of the company's shares are sold short. View Opko Health's Current Options Chain.

Who are some of Opko Health's key competitors?

What other stocks do shareholders of Opko Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opko Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), bluebird bio (BLUE), Gray Television (GTN), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Allergan (AGN), Novavax (NVAX) and AT&T (T).

Who are Opko Health's key executives?

Opko Health's management team includes the following people:
  • Dr. Phillip Frost, Chairman & CEO (Age 83)
  • Dr. Jane H. Hsiao M.B.A., Ph.D., MBA, Vice Chairman & CTO (Age 72)
  • Mr. Adam E. Logal, Sr. VP, CFO, Chief Accounting Officer & Treasurer (Age 41)
  • Mr. Steven D. Rubin, Exec. VP of Admin. & Director (Age 59)
  • Ms. Kate Inman, Gen. Counsel & Sec. (Age 46)

What is Opko Health's stock symbol?

Opko Health trades on the NASDAQ under the ticker symbol "OPK."

How do I buy shares of Opko Health?

Shares of OPK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Opko Health's stock price today?

One share of OPK stock can currently be purchased for approximately $1.36.

How big of a company is Opko Health?

Opko Health has a market capitalization of $910.97 million and generates $901.90 million in revenue each year. The biotechnology company earns $-314,920,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. Opko Health employs 6,096 workers across the globe. View additional information about Opko Health.

What is Opko Health's official website?

The official website for Opko Health is http://www.opko.com/.

How can I contact Opko Health?

Opko Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The biotechnology company can be reached via phone at 305-575-4100 or via email at [email protected]


MarketBeat Community Rating for Opko Health (NASDAQ OPK)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  453 (Vote Outperform)
Underperform Votes:  446 (Vote Underperform)
Total Votes:  899
MarketBeat's community ratings are surveys of what our community members think about Opko Health and other stocks. Vote "Outperform" if you believe OPK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel